Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can PET scans reveal if amyloidosis treatment is working?

NCT ID NCT07829705

NEW Diagnosis Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are testing whether beta-amyloid PET/CT scans can detect changes in heart amyloid deposits after one year of treatment for light chain cardiac amyloidosis. Sixty adults with newly diagnosed AL-CA receive standard anti-plasma cell or targeted therapy and undergo PET/CT scans with 11C-PIB or 18F-Florbetapir at baseline and 12 months. The study measures changes in heart tracer uptake to see if imaging can track therapeutic response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
11C-PIB and 18F-Florbetapir, two beta-amyloid PET imaging tracers
What this could lead to
If the scans track treatment response, doctors could use them to adjust therapy earlier for people with light chain cardiac amyloidosis.
What could go wrong
The study is small and single-center, so the scan changes may not reflect real clinical improvement or apply to all patients. PET scans also involve radiation exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2020

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 y； 2. were proven newly diagnosed AL-CA by standard criteria; 3. subsequently received first-line therapies including anti-plasma cell therapy or targeted therapy; 4. must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements. Exclusion Criteria: 1. received therapy with an approved treatment (e.g., Bortezomib, Daratumumab) prior to enrollment; 2. pregnancy or breastfeeding; 3. severe claustrophobia; 4. any condition deemed by the investigator to interfere with study results or increase participant risk.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Light chain cardiac amyloidosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AL amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Light chain cardiac amyloidosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.